Jakarta (19/07), In assisting clinicians in determining prognosis, type of therapy, and risk of congenital disease in colorectal cancer patients, PT Bio Farma collaborated with Pathgen, Dharmais Cancer Hospital, BRIN, RSCM, UI, UGM, Dr. RSUP. Sardjito, University of Riau, University of Muhammadiyah Purwokerto, Indonesian Embassy in London, and Nottingham University developed the BioColomelt-Dx product. The Minister of Health (Menkes) of the Republic of Indonesia Budi Gunadi Sadikin, together with the President Director of PT. Bio Farma Honesti Basyir, Head of the Government Goods/Services Procurement Policy Institute (LKPP) Abdullah Azwar Anas, and Director of the Dharmais Cancer Hospital Soeko W Nindito have officially inaugurated the launch of innovative products for the nation’s children, especially in the health and technology fields on July 19, 2022. The launch was held offline at the Dharmais Cancer Hospital Auditorium and online via the zoom application.
The idea for a colon cancer test kit product was initiated by the CEO of Pathgen Diagnostic Technology, Susanti, as a cancer survivor herself. At the age of 30, he was diagnosed with stage 3 colorectal cancer and had to undergo several surgeries, chemotherapy, and various treatments in Indonesia. With this experience, after being declared remission began to develop colon cancer diagnostic kits in Indonesia with various parties.
BioColoMelt Dx is expected to help with low-cost cancer treatment in Indonesia by utilizing PCR technology and high-resolution melting analysis (HRM). This kit provides the right therapeutic information for the patient and can detect hereditary genetics, so that prevention can be carried out as early as possible for the patient’s family. This is a relevant advantage to be applied as a point of care (POC) service throughout Indonesia, especially in the post-COVID-19 pandemic era.